STING1 and neoplasm: Our molecular design was initiated with a recently disclosed STING agonist, MSA-2 (Fig. 1A), identified by Merck.16MSA-2 is the first orally available non-nucleotide STING agonist having tremendous potency in vivo in various mouse syngeneic tumor models.